Immune Monitoring and Biospecimen Core

项目总结/摘要 免疫监测和生物标本（IMB）核心致力于提供卓越的领导力， U19需要免疫监测和生物标本科学方面的专业知识，以开发新型有效药物 可以穿过血脑屏障（BBB）并在临床上进行测试。作为一个团队， 加州大学旧金山弗朗西斯科和西北大学的研究人员将获取、处理和 分析来自入组患者和GBM临床前模型的生物标本。许多程序 实现这些目标所需的是非标准的，需要专业知识和复杂的 实验分析此外，核心将提供人类胶质瘤的组织病理学和分子分析 异种移植物，中心组织病理学审查，并确保生物标本各方面的严格质量控制 装卸.核心方案将根据以下具体目标满足这些需求： 具体目标 1.为获取和保存高质量的脑肿瘤患者提供人员和专业知识 生物标本和临床前模型，以满足项目和临床的组织累积要求 审判 2.提供常规和先进的组织处理/加工和分析技术和专业知识， 人和鼠肿瘤，包括高维流式细胞术，多重免疫荧光， Cytek和单细胞RNA测序，这将推动项目假设的发展和目标 成就 3.提供神经病理学专业知识，以解释肿瘤组织并提取适当的 定量和半定量参数。 4.对核心活动进行一致的监督，以确保严格遵守法规 管理知情同意和患者保密，以及生物标本和 来自生物标本的信息。

PROJECT SUMMARY/ABSTRACT The Immune Monitoring and Biospecimen (IMB) Core is a dedicated to provide the outstanding leadership and expertise in immune monitoring and biospecimen sciences needed in this U19 to develop novel effective agents that can cross the blood brain barrier (BBB) and test them in the clinic. Working collaboratively as a team the investigators at University of California San Francisco and Northwestern University will acquire, process, and analyze biospecimens from enrolled patients and from preclinical models for GBM. Many of the procedures required to achieve these objectives are non-standard, requiring specialized knowledge and sophisticated experimental analysis. In addition, the Core will provide histopathologic and molecular analyses of human glioma xenografts, central histopathologic review, and ensure strict quality control in all aspects of biospecimen handling. The Core will address these needs based on the following specific aims: Specific Aims 1. To provide the staff and expertise for the acquisition and preservation of high-quality brain tumor patient biospecimens and preclinical models to meet the tissue accrual requirements for the projects and clinical trials. 2. To provide routine and advanced tissue handling/processing and analytical techniques and expertise for human and murine tumors, including high-dimensional flow cytometry, multiplex immunoflourescence, Cytek, and single cell RNA sequencing, that will advance project hypothesis development and goal attainment. 3. To provide the neuropathologic expertise for interpretation of the tumor tissue and extraction of appropriate quantitative and semi-quantitative parameters. 4. To provide consistent oversight of the Core activities that will ensure the stringent compliance with regulations governing informed consent and patient confidentiality, as well as management of the biospecimens and the information derived from the biospecimens.